SHARE-BASED COMPENSATION (Tables)
|
3 Months Ended |
12 Months Ended |
Mar. 31, 2023 |
Dec. 31, 2022 |
| Equity [Abstract] |
|
|
| Schedule of common stock reserved for future issuance under employee stock plans |
|
| Schedule of common stock reserved for future issuance under employee stock plans |
|
|
|
|
| Plans |
|
Number of
Shares |
|
| Total awards available to be issued |
|
|
2,742,509 |
|
| Total awards outstanding |
|
|
12,079,924 |
|
| Total Common Stock reserved for future issuance under employee stock plans |
|
|
14,822,433 |
|
|
| Schedule of summarizes share-based compensation expense |
| Schedule of summarizes share-based compensation expense |
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
March 31, |
|
| |
|
2023 |
|
|
2022 |
|
| Research and development |
|
$ |
531 |
|
|
$ |
966 |
|
| Sales and marketing |
|
|
507 |
|
|
|
1,083 |
|
| General and administrative |
|
|
894 |
|
|
|
4,474 |
|
| Cost of sales |
|
|
7 |
|
|
|
41 |
|
| Total share-based compensation |
|
$ |
1,939 |
|
|
$ |
6,564 |
|
|
| Schedule of summarizes share-based compensation expense |
|
|
|
|
|
|
|
|
| |
|
December 31, |
|
| |
|
2022 |
|
|
2021 |
|
| Research and development |
|
$ |
3,554 |
|
|
$ |
1,812 |
|
| Sales and marketing |
|
|
3,491 |
|
|
|
1,925 |
|
| General and administrative |
|
|
13,842 |
|
|
|
6,759 |
|
| Cost of sales |
|
|
243 |
|
|
|
81 |
|
| Total share-based compensation |
|
$ |
21,130 |
|
|
$ |
10,577 |
|
|
| Schedule of fair value of the stock options assumptions |
| Schedule of assumptions |
|
|
|
|
|
|
|
|
| |
Post-
Combination
Warrants |
|
Private
Placement
Warrants |
|
| Assumptions: |
|
|
|
|
|
|
|
|
| Stock price |
|
$ |
0.69 |
|
|
$ |
0.69 |
|
| Exercise price |
|
$ |
12.50-17.50
|
|
|
$ |
11.50 |
|
| Risk free rate |
|
|
4.78 |
% |
|
|
3.66 |
% |
| Expected volatility |
|
|
101.1 |
% |
|
|
84.20 |
% |
| Dividend yield |
|
|
0.00 |
% |
|
|
0.00 |
% |
|
| Schedule of fair value of the stock options assumptions |
|
|
|
|
|
|
|
|
| |
|
Year Ended
December 31, |
|
| |
|
2022 |
|
|
2021 |
|
| Weighted-average grant date price of our common stock (per share) |
|
$ |
2.21 |
|
|
$ |
3.99 |
|
| Risk-free interest rate |
|
|
4 |
% |
|
|
1.19 |
% |
| Expected volatility |
|
|
76 |
% |
|
|
33.0 |
% |
| Expected term (in years) |
|
|
5 |
|
|
|
5 |
|
| Expected dividend yield |
|
|
- |
% |
|
|
- |
% |
|
| Schedule of common stock options |
| Schedule of common stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Number of
Shares |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contractual
Life (Years) |
|
|
Weighted-
Average
Grant Date
Fair Value |
|
| Outstanding, December 31, 2022 |
|
|
7,812,178 |
|
|
$ |
3.70 |
|
|
|
6.56 |
|
|
$ |
2.23 |
|
| Forfeited |
|
|
(31,523 |
) |
|
|
2.26 |
|
|
|
- |
|
|
|
1.46 |
|
| Expired |
|
|
(14,421 |
) |
|
|
5.40 |
|
|
|
- |
|
|
|
2.86 |
|
| Outstanding, March 31, 2023(a) |
|
|
7,766,234 |
|
|
$ |
3.70 |
|
|
|
6.32 |
|
|
$ |
1.98 |
|
| Exercisable, March 31, 2023(b) |
|
|
4,870,164 |
|
|
$ |
4.03 |
|
|
|
4.87 |
|
|
$ |
2.12 |
|
| (a) |
There
was no aggregate intrinsic value of all stock options outstanding as of March 31, 2023. |
| (b) |
There
was no aggregate intrinsic value of all vested/exercisable stock options as of March 31, 2023. |
|
| Schedule of common stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Number of
Shares |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contractual
Life (Years) |
|
|
Weighted-
Average
Grant
Date Fair
Value |
|
| Outstanding, December 31, 2021 |
|
|
5,489,492 |
|
|
$ |
4.23 |
|
|
|
6.05 |
|
|
$ |
2.27 |
|
| Granted |
|
|
2,686,337 |
|
|
|
2.81 |
|
|
|
|
|
|
|
2.21 |
|
| Forfeited |
|
|
(65,634 |
) |
|
|
4.50 |
|
|
|
|
|
|
|
2.52 |
|
| Expired |
|
|
(298,017 |
) |
|
|
5.26 |
|
|
|
|
|
|
|
2.82 |
|
| Outstanding, December 31, 2022(a) |
|
|
7,812,178 |
|
|
$ |
3.70 |
|
|
|
6.56 |
|
|
$ |
2.23 |
|
| Exercisable, December 31, 2022(b) |
|
|
4,525,905 |
|
|
$ |
4.03 |
|
|
|
4.84 |
|
|
$ |
2.13 |
|
| (a) |
There was no aggregate intrinsic value of all stock options outstanding as of December 31, 2022. |
| (b) |
There was no aggregate intrinsic value of all vested/exercisable stock options as of December 31, 2022. |
|
| Schedule of Unvested Restricted Stock Units |
| Schedule of Unvested Restricted Stock Units |
|
|
|
|
|
|
|
|
| |
|
Number of
RSUs |
|
|
Weighted
Average
Grant Date
Fair Value |
|
| Outstanding (nonvested), December 31, 2022 |
|
|
4,267,746 |
|
|
$ |
3.58 |
|
| Released |
|
|
(387,204 |
) |
|
|
5.44 |
|
| Forfeited |
|
|
(49,610 |
) |
|
|
3.07 |
|
| Outstanding (nonvested), March 31, 2023 |
|
|
3,830,932 |
|
|
$ |
3.41 |
|
|
| Schedule of restricted stock awards |
|
|
|
|
|
|
|
|
| |
|
Number of
Shares |
|
|
Weighted
Average
Grant Date
Fair Value |
|
| Outstanding (nonvested), December 31, 2021 |
|
|
351,831 |
|
|
$ |
9.63 |
|
| Vested |
|
|
(345,471 |
) |
|
|
9.75 |
|
| Cancelled |
|
|
(6,360 |
) |
|
|
9.63 |
|
| Outstanding (nonvested), December 31, 2022 |
|
|
- |
|
|
$ |
- |
|
|
| Schedule of restricted stock units |
|
| Schedule of restricted stock units |
|
|
|
|
|
|
|
|
| |
|
Number of
RSUs |
|
|
Weighted
Average
Grant Date
Fair Value |
|
| Outstanding (nonvested), December 31, 2021 |
|
|
2,962,884 |
|
|
$ |
8.60 |
|
| Granted |
|
|
3,635,878 |
|
|
|
2.92 |
|
| Released |
|
|
(2,108,735 |
) |
|
|
9.17 |
|
| Forfeited |
|
|
(222,281 |
) |
|
|
6.50 |
|
| Outstanding (nonvested), December 31, 2022 |
|
|
4,267,746 |
|
|
$ |
3.58 |
|
|